Immunotherapy for Solitary Fibrous Tumor (Hemangiopericytoma): A Unique Treatment Approach for a Rare Central Nervous System Tumor

Lauren Singer, Jorie Singer, Craig Horbinski, Marta Penas-Prado, Rimas V. Lukas

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: Solitary fibrous tumors (SFTs) of the central nervous system represent a unique entity with limited data on best treatment practices. CASE REPORT: Here, we present a case of multiply recurrent central nervous system SFT treated with radiation and immunotherapy. Immunotherapy was chosen based on mutations of genes encoding DNA repair enzymes detected through next-generation sequencing of the tumor, DNA polymerase epsilon catalytic subunit ( POLE ) and mutL homolog 1. The use of radiation and immunotherapy led to slight shrinkage and no recurrence of the tumor for over 2 years. CONCLUSION: The presence of somatic DNA repair enzyme gene mutations in SFT may suggest a benefit from a combination of radiotherapy and immunotherapy. This may serve as a biomarker for guiding management in patients with this rare tumor.

Original languageEnglish (US)
Pages (from-to)250-253
Number of pages4
JournalThe neurologist
Volume29
Issue number4
DOIs
StatePublished - Jul 1 2024

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Immunotherapy for Solitary Fibrous Tumor (Hemangiopericytoma): A Unique Treatment Approach for a Rare Central Nervous System Tumor'. Together they form a unique fingerprint.

Cite this